



# Leukaemia UK

Blood cancer care and cure

**Annual Report**  
2017

# Contents

<b>Report from the Chairman and Board of Trustees</b>	<b>3</b>
• New beginnings built on strong foundations	4
• How we made a difference in 2017 to families affected by blood cancer	5
• Scientific and Clinical Research	5
• Blood Cancer Care Revolution – Mind and Body Team	6
• Helping Hand Fund	6
• Funding excellent facilities and educational initiatives	6
<b>Chief Executive’s Update</b>	<b>7</b>
<b>Looking ahead</b>	<b>8</b>
<b>Financial Statements</b>	<b>9</b>

# Report from the Chairman and Board of Trustees

We make a difference to families affected by blood cancer only thanks to the generosity and dedication of our supporters. We are grateful and touched by those who donated in memory of someone affected by blood cancer, to those who took on a challenge to raise funds for our cause plus all the Trusts and Foundations who have supported our work for many years, and to all individuals who give their time, effort and money with such generosity.

Thank you for your support and for being part of our exciting journey towards improving care for families affected by blood cancers, and in seeking out innovative research and treatment pathways.



## New beginnings built on strong foundations

**For the last four decades, Leukaemia UK has been making a difference to those living with blood cancer as we understand that behind every diagnosis are families and individuals who need help.**

We will support those affected by blood cancer, and their family and friends, through the physical, psychological and financial uncertainty that lies ahead.

For 40 years Leukaemia UK has been working to fund innovative and effective research into finding a cure and better treatments for leukaemia, lymphoma, myeloma and other blood disorders.

In 2017, our 40<sup>th</sup> anniversary, we looked back over our achievements, and reviewed the context we are working in, in order to develop a strategy and vision for the future which is relevant to patient needs today, and fills gaps in provision. We aim to increase our impact by supporting more families affected by blood cancer and by working with more hospitals around the UK.

2017 felt like the right time to change our name from the Elimination of Leukaemia Fund to Leukaemia UK to help us achieve our ambitions. We still hold tight to the founding principles of this charity which are:

- to improve care and support for people living with blood cancer
- to fund innovative research to find kinder, more effective ways of treating blood cancer

Frontera, a creative digital agency, helped us develop a new name, logo and brand, at no cost to our supporters.

Our new name, Leukaemia UK, reflects our strategic aims to work throughout the UK, working for a blood cancer cure and improved care and also to build awareness of the diseases. Our work continues to cover all blood cancers and blood related disorders.

Our name change took effect in November 2017 and we have been delighted with the overwhelming positive response from our supporters, stakeholders and peers in the field following our rebrand. Our name change didn't affect our charity registration number, office address, bank details or company numbers.

This year has also seen us broaden the skills and experience base of the Trustee Board, bringing on younger members with digital and marketing skills to support our growth and development. Stronger Governance and a great focus on our Board's diversity and skills will add to the charity's ability to develop in the coming year.



**Leukaemia UK**  
Blood cancer care and cure

## How we made a difference in 2017 to families affected by blood cancer

### Scientific and Clinical Research

Blood cancer treatments can take their toll on patients and can involve long periods of isolation. Our work is not only focused on research for a cure but also for kinder treatments.

This year we identified an unmet need in the funding of trainee haematologists, just starting out in the specialty, for projects relating to haematological malignancies, or patients suffering from these conditions.

We were looking for bold ideas to not only improve the treatment of patients, but also nurture future talent by providing the applicants with the opportunity to develop the skills and enthusiasm to become haematology researchers and innovators of the future.

Following its very successful pilot in 2017, the programme will be relaunched in 2018 to include nursing staff and Allied Health Professionals in the field. This broadening will not only address an unmet need, but also align more closely with our remit.

“Leukaemia UK kindly provided a small grant to support an iBSc project. Elliot Byford proved to be an excellent student and I am pleased to say that today he had a paper published in the journal PLOS One. This is an impressive output for a 9 month iBSc project. As a result of his experience Elliot is keen to pursue a career in academic haematology and this publication will prove an excellent platform for him to build on. We are very grateful for the support from Leukaemia UK without which the project would not have been possible.”

Matt Ahearne, Clinical Lecturer in Haematology, University of Leicester

Two pieces of work on non-Hodgkin lymphoma concluded in 2017, with one by Dr Robert Carr investigating the recovery rates in young adults attracting international interest, and leveraging in follow-on funding from the Gilead Fellowship. The other, using MRI scanning to identify non-responders has still to report conclusions at time of writing.



## Blood Cancer Care Revolution – Mind and Body Team

The key learning from our earlier funding of counsellor posts, and the specialist Teenagers and Young Adults (TYA) Clinical Psychologist at Guys and St Thomas' Trust was the impact made in patients' ability to cope with the harsh treatment regimes and their improved ability to get back to a normal life pathway after treatments. To build further on these positive outcomes we have decided to invest in a significant pilot project at King's College Hospital London, (the first service of its kind) delivering bespoke Mind and Body treatment pathways.

We are funding a multi-disciplinary Mind and Body team headed by a psychiatrist (in liaison with The Maudsley Institute, and under the Mind and Body Programme umbrella at King's), with support from a Consultant Haematologist, Clinical Psychologist, Social Worker and an Allied Health Professional. Training in new care pathways will also be given extensively to existing staff.

Through the Leukaemia UK Mind and Body Team, people affected by blood cancer will routinely receive psychological support where needed. It is hoped that by making emotional support an integral part of everyone's treatment, psychological problems may be identified early or even avoided altogether.

The pilot will be launched in 2018 and will be evaluated in the context of proving that such recognition of the emotional strain and turmoil that any blood cancer treatment regime involves, will

improve outcomes. Assuming the impacts from the pilot are as expected, our ambition is to develop other such programmes throughout the UK.

## Helping Hand Fund

We have continued providing financial help to those in need due to their blood cancer diagnosis. Dealing with an unexpected illness can knock life plans off course for a while which can sometimes have significant financial repercussions. We know this can be a real worry. Leukaemia UK is pleased to be able to offer a one-off grant through our Helping Hand Fund to ease families or individuals through a difficult period.

*“Thank you so much for your financial support, it means an incredible amount to me, these things make a huge difference in my life”*

A Helping Hand Fund recipient from London, who received £500 to support them with travelling costs due to their lymphoma treatment.

## Funding excellent facilities and educational initiatives

Opened in April 2017, we were proud to fund the building and staffing of a new Ambulatory Care Unit which supports patients undergoing transplants on an outpatient basis - yet another major step forward in patient care.

In 2017 we also funded a key educational initiative led by a dietician at Guy's Hospital London for teenagers and young adults affected by blood cancer.



# Chief Executive's Update

**I am incredibly proud of the step-change in our charity achieved this year. Over its 40 years our charity has set in place some significant foundations of achieving transformational change in the delivery of haematology care at Kings in London our primary partner. Our newly agreed strategy puts this into a wider context of need in the sector, and complements the work of others, whilst staying true to our founders' commitment to improve care for people with any blood cancer or blood related disorder.**



I have now set in place the significant internal changes needed to create an efficient and effective 21<sup>st</sup> century charity, and this, which will deliver on our new strategy in the most cost-effective way possible, is what will enable us to grow and engender significant change for blood cancer patients.

The rebranding, and the innovative marketing campaign for the Mind and Body team offered to us by Frontera pro bono is valued at £60,850 in our accounts. The rebranding also gave us the opportunity of building a new website, for which we qualified for grant funding from the Transform Foundation, valued at £18,000. We are extremely grateful for both of these investments, which have helped us build a solid platform for growth, at minimal cost.

We also moved to having a single CRM database to house all our data, which will ensure we are ready for the new GDPR regulations. Whilst it has

always been our policy to respect our donors' privacy, and not to share data with outside organisations for marketing purposes, we are now well positioned to handle new regulations, and also to be able to give added stewardship to the donors who so generously support us.

The new branding and charity name 'Leukaemia UK', was well received by our stakeholders and supporters throughout our re-branding process and following our new brand launch. Whilst we have always had 'leukaemia' in our name, we are very much a charity for all blood cancers and blood disorders, and have reflected that in our new strapline 'Blood cancer care and cure'.

Our mission remains firmly to support families affected by blood cancer or other blood related illnesses, by continuing our work in research, care and patient well-being.



We have ambitious plans for next year as we move to implement our new strategy, which combines research with a unique approach to mental health that is our 'Mind and Body Team.' A significant proportion of people with blood cancer suffer from depression, anxiety and loss of control, and some face severe mental and emotional battles to come to terms with their new reality after diagnosis and following recovery.

We have seen clear evidence of the difference made by counselling, as people are taught coping mechanisms, and have a safe space to share their anxieties, since we funded the first dedicated haematology counsellor in the UK around 10 years ago. Such posts are now commonly accepted as part of the treatment pathway. We are now taking this to the next level with our Mind and Body programme, which will provide academic analysis of the impact made by such care, and much better identification of all mental health problems which can so often accompany a cancer diagnosis. We look forward to publishing these findings by 2020.

None of this would be possible without the skills and dedication of our staff, Trustees, and other volunteers, who all bring a particularly valuable contribution in their time and skills. As a charity that is completely reliant on voluntary donations and we are proud of our journey travelled in 2017 thanks to our supporters' generosity.



Charity walk for peace cheque presentation December 2017

I'd like to make a special mention of the Hewson family who have supported Leukaemia UK in celebration of their son Carl's life, we have been overwhelmed by Carl's friends and family's fundraising efforts and are so very grateful for their ongoing kind support. Another mention goes to the Ahmidayya Muslim Elders Association who again selected us as one of their chosen charities kindly donating funds for our cause. Thank you to them, and to all of our supporters who make it possible for us a lasting difference to families affected by blood cancer.

**Angela Smith-Morgan**  
CEO

## Looking ahead



The charity moves into 2018 with a strong foundation for development, with new IT systems and digital platforms allowing us to keep overheads low as we grow. Our aim is very much to ensure that our charity fills unmet needs in blood cancer care, and anticipates new needs in the area of blood cancer and blood disorder treatments. We are building relationships with other blood cancer charities in the field, we are proud to be part of the All-Party Parliamentary Group on Blood Cancer (APPG), in order to ensure our offer is always complementary, and remains true to our founding vision of focussing on patient care.

**Alastair Adam**  
Chair of Trustees



**REGISTERED COMPANY NUMBER: 08318908 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1150414**

**Report of the Trustees and  
Unaudited Financial Statements for the Year Ended 31 December 2017  
for**

**Leukaemia UK Ltd**

**(formerly The Elimination  
of Leukaemia Fund Ltd)**

Geoffrey Cole & Co Ltd  
4 Reading Road  
Pangbourne  
Berkshire  
RG8 7LY

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Contents of the Financial Statements  
for the Year Ended 31 December 2017**

	Page
Report of the Trustees	1
Independent Examiner's Report	2
Statement of Financial Activities	3
Statement of Financial Position	4 to 5
Notes to the Financial Statements	6 to 10
Detailed Statement of Financial Activities	11 to 12

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Report of the Trustees  
for the Year Ended 31 December 2017**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2017. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

08318908 (England and Wales)

**Registered Charity number**

1150414

**Registered office**

4 Reading Road  
Pangbourne  
Reading  
Berkshire  
RG8 7LY

**Trustees**

A R Adam	Accountant
Professor A Pagliuca	Company Director
J Neal	Company Director
Dr R Carr	Company Director - resigned 23.8.2017
Ms C Evans	Company Director
Ms L Pepper	Company Director
Mrs A L Stewart	Company Director - appointed 24.7.2017
Miss J R Coleman	Company Director - appointed 24.7.2017

**Independent examiner**

Geoffrey Cole & Co Ltd  
4 Reading Road  
Pangbourne  
Berkshire  
RG8 7LY

Approved by order of the board of trustees on ..... and signed on its behalf by:

.....  
A R Adam - Trustee

**Independent Examiner's Report to the Trustees of  
Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Independent examiner's report to the trustees of Leukaemia UK Ltd ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2017.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached

Geoffrey Cole  
ICAEW  
Geoffrey Cole & Co Ltd  
4 Reading Road  
Pangbourne  
Berkshire  
RG8 7LY

Date: .....

**Leukaemia UK Ltd**  
**(formerly The Elimination**  
**of Leukaemia Fund Ltd)**

**Statement of Financial Activities**  
**for the Year Ended 31 December 2017**

	Not es	Unrestricted fund £	Restricted fund £	2017 Total funds £	2016 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		240,851	2,000	242,851	141,790
Other trading activities	2	74,863	-	74,863	74,487
Investment income	3	<u>1,269</u>	-	<u>1,269</u>	<u>2,588</u>
<b>Total</b>		<b>316,983</b>	<b>2,000</b>	<b>318,983</b>	<b>218,865</b>
 <b>EXPENDITURE ON</b>					
Raising funds		30,552	-	30,552	28,510
<b>Charitable activities</b>	4				
CTU - Kings		-	2,000	2,000	-
Project Grants		442,773	-	442,773	46,547
Patient Aid Grants		1,977	-	1,977	2,000
Fellowships		514	-	514	-
General		86,626	-	86,626	78,437
Services in Kind		<u>60,850</u>	-	<u>60,850</u>	-
<b>Total</b>		<b>623,292</b>	<b>2,000</b>	<b>625,292</b>	<b>155,494</b>
<b>NET INCOME/(EXPENDITURE)</b>		<b>(306,309)</b>	<b>-</b>	<b>(306,309)</b>	<b>63,371</b>
 <b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		<b>533,849</b>	<b>-</b>	<b>533,849</b>	<b>470,478</b>
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b><u>227,540</u></b>	<b><u>-</u></b>	<b><u>227,540</u></b>	<b><u>533,849</u></b>

**CONTINUING OPERATIONS**

All income and expenditure has arisen from continuing activities.

**Leukaemia UK Ltd**  
**(formerly The Elimination**  
**of Leukaemia Fund Ltd)**

**Statement of Financial Position**  
**At 31 December 2017**

		Unrestricted fund	Restricted fund	2017 Total funds	2016 Total funds
	Not es	£	£	£	£
<b>FIXED ASSETS</b>					
Tangible assets	9	466	-	466	354
<b>CURRENT ASSETS</b>					
Debtors	10	7,925	-	7,925	4,471
Cash at bank		<u>892,279</u>	<u>-</u>	<u>892,279</u>	<u>835,540</u>
		900,204	-	900,204	840,011
<b>CREDITORS</b>					
Amounts falling due within one year	11	<u>(442,288)</u>	<u>-</u>	<u>(442,288)</u>	<u>(272,141)</u>
<b>NET CURRENT ASSETS</b>		<u>457,916</u>	<u>-</u>	<u>457,916</u>	<u>567,870</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		458,382	-	458,382	568,224
<b>CREDITORS</b>					
Amounts falling due after more than one year	12	<u>(230,842)</u>	<u>-</u>	<u>(230,842)</u>	<u>(34,375)</u>
<b>NET ASSETS</b>		<u>227,540</u>	<u>-</u>	<u>227,540</u>	<u>533,849</u>
<b>FUNDS</b>					
Unrestricted funds	13			227,540	533,849
Restricted funds				<u>-</u>	<u>-</u>
<b>TOTAL FUNDS</b>				<u>227,540</u>	<u>533,849</u>

The notes form part of these financial statements

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Statement of Financial Position - continued  
At 31 December 2017**

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2017 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to charitable small companies.

The financial statements were approved by the Board of Trustees on ..... and were signed on its behalf by:

.....  
A R Adam -Trustee

.....  
J Neal -Trustee

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements  
for the Year Ended 31 December 2017**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 50% on cost

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**2. OTHER TRADING ACTIVITIES**

	<b>2017</b>	2016
	£	£
Fundraising events	<b>71,627</b>	74,230
Lottery Income	<b><u>3,236</u></b>	<u>257</u>
	<b><u>74,863</u></b>	<u>74,487</u>



**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2017**

**3. INVESTMENT INCOME**

	<b>2017</b>	<b>2016</b>
	<b>£</b>	<b>£</b>
Deposit account interest	<u><b>1,269</b></u>	<u><b>2,588</b></u>

**4. CHARITABLE ACTIVITIES COSTS**

In the year ended 31 December 2017 there was an in kind donation from Frontera London Ltd of £60,850, this is included in Income within Donations and Legacies and as Expenditure as Services in Kind.

**5. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	<b>2017</b>	<b>2016</b>
	<b>£</b>	<b>£</b>
Depreciation - owned assets	<u><b>254</b></u>	<u><b>93</b></u>

**6. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 December 2017 nor for the year ended 31 December 2016.

**Trustees' expenses**

There were no trustees' expenses paid for the year ended 31 December 2017 nor for the year ended 31 December 2016.

**7. STAFF COSTS**

The average monthly number of employees during the year was as follows:

	<b>2017</b>	<b>2016</b>
	<u><b>-</b></u>	<u><b>-</b></u>

No employees received emoluments in excess of £60,000.

**8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	<b>Unrestricted fund</b>	<b>Restricted fund</b>	<b>Total funds</b>
	<b>£</b>	<b>£</b>	<b>£</b>
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	<b>141,790</b>	-	141,790
Other trading activities	<b>74,487</b>	-	74,487
Investment income	<u><b>2,588</b></u>	<u>-</u>	<u><b>2,588</b></u>
<b>Total</b>	<b>218,865</b>	-	218,865
<b>EXPENDITURE ON</b>			
Raising funds	<b>28,510</b>	-	28,510
<b>Charitable activities</b>			
Carried forward			

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2017**

<b>8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued</b>	<b>Unrestricted fund £</b>	<b>Restricted fund £</b>	<b>Total funds £</b>
<b>Charitable activities</b>			
Brought forward			
Project Grants	24,562	21,985	46,547
Patient Aid Grants	2,000	-	2,000
General	<u>78,437</u>	<u>-</u>	<u>78,437</u>
<b>Total</b>	<u>133,509</u>	<u>21,985</u>	155,494
<b>NET INCOME/(EXPENDITURE)</b>	<b>85,356</b>	<b>(21,985)</b>	63,371
<b>RECONCILIATION OF FUNDS</b>			
<b>Total funds brought forward</b>	<u>448,493</u>	<u>21,985</u>	470,478
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u>533,849</u>	<u>-</u>	<u>533,849</u>
<b>9. TANGIBLE FIXED ASSETS</b>			<b>Computer equipment £</b>
<b>COST</b>			
At 1 January 2017			931
Additions			<u>366</u>
At 31 December 2017			<u>1,297</u>
<b>DEPRECIATION</b>			
At 1 January 2017			577
Charge for year			<u>254</u>
At 31 December 2017			<u>831</u>
<b>NET BOOK VALUE</b>			
At 31 December 2017			<u>466</u>
At 31 December 2016			<u>354</u>
<b>10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR</b>			
		<b>2017</b>	2016
		£	£
Other debtors		<u>7,925</u>	<u>4,471</u>

**Leukaemia UK Ltd**  
**(formerly The Elimination**  
**of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued**  
**for the Year Ended 31 December 2017**

**11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2017	2016
	£	£
Trade creditors	26,101	37,837
Accrued expenses	1,913	1,800
Grant commitments	<u>414,274</u>	<u>232,504</u>
	<u><b>442,288</b></u>	<u><b>272,141</b></u>

**12. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**

	2017	2016
	£	£
Grant commitments	<u>230,842</u>	<u>34,375</u>

**13. MOVEMENT IN FUNDS**

	At 1.1.17	Net movement in funds	At 31.12.17
	£	£	£
<b>Unrestricted funds</b>			
General fund	533,849	(306,309)	227,540
	<u>533,849</u>	<u>(306,309)</u>	<u>227,540</u>
<b>TOTAL FUNDS</b>	<u><b>533,849</b></u>	<u><b>(306,309)</b></u>	<u><b>227,540</b></u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
<b>Unrestricted funds</b>			
General fund	316,983	(623,292)	(306,309)
<b>Restricted funds</b>			
Project Grants	2,000	(2,000)	-
	<u>318,983</u>	<u>(625,292)</u>	<u>(306,309)</u>
<b>TOTAL FUNDS</b>	<u><b>318,983</b></u>	<u><b>(625,292)</b></u>	<u><b>(306,309)</b></u>

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2017**

**13. MOVEMENT IN FUNDS - continued**

**Comparatives for movement in funds**

	At 1.1.16 £	Net movement in funds £	At 31.12.16 £
<b>Unrestricted Funds</b>			
General fund	448,493	85,356	533,849
<b>Restricted Funds</b>			
Project Grants	21,985	(21,985)	-
	<u>470,478</u>	<u>63,371</u>	<u>533,849</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	218,865	(133,509)	85,356
<b>Restricted funds</b>			
Project Grants	-	(21,985)	(21,985)
	<u>218,865</u>	<u>(155,494)</u>	<u>63,371</u>

**14. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 December 2017.

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Detailed Statement of Financial Activities  
for the Year Ended 31 December 2017**

	2017 £	2016 £
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Donations	182,001	141,790
Donated services and facilities	<u>60,850</u>	<u>-</u>
	<b>242,851</b>	141,790
<b>Other trading activities</b>		
Fundraising events	71,627	74,230
Lottery Income	<u>3,236</u>	<u>257</u>
	<b>74,863</b>	74,487
<b>Investment income</b>		
Deposit account interest	<u>1,269</u>	<u>2,588</u>
<b>Total incoming resources</b>	<b>318,983</b>	218,865
<b>EXPENDITURE</b>		
<b>Raising donations and legacies</b>		
Cost of fundraising	30,552	28,417
Computer equipment	<u>-</u>	<u>93</u>
	<b>30,552</b>	28,510
<b>Charitable activities</b>		
Wages	-	15,722
Fundraising support staff	24,390	8,796
Chief executive officer	30,300	27,750
Grants to institutions	<u>447,264</u>	<u>56,037</u>
	<b>501,954</b>	108,305
<b>Support costs</b>		
<b>Management</b>		
Rates and water	7,734	8,214
Insurance	224	564
Telephone	130	662
Postage and stationery	820	1,325
Sundries	258	1,585
IT support	951	1,558
Website and branding	11,525	-
Trust fundraiser	3,854	-
Donated services	60,850	-
Computer equipment	<u>254</u>	<u>-</u>
	<b>86,600</b>	13,908

This page does not form part of the statutory financial statements

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Detailed Statement of Financial Activities  
for the Year Ended 31 December 2017**

	2017 £	2016 £
<b>Finance</b>		
Bank charges	60	10
<b>Governance costs</b>		
Accountancy fees	2,716	1,896
Legal fees	<u>3,410</u>	<u>2,865</u>
	<u>6,126</u>	<u>4,761</u>
<b>Total resources expended</b>	<b>625,292</b>	155,494
	_____	_____
<b>Net (expenditure)/income</b>	<b><u>(306,309)</u></b>	<u>63,371</u>

This page does not form part of the statutory financial statements

**Leukaemia UK is a fantastic organisation that is there to care for people going through blood cancer. Its whole ethos is to help improve treatment plans and outcomes for haematological patients.**

Gavin Maynard-Wyatt, lead cancer nurse, Guy's Hospital in London

**It is great to know that if someone is facing a leukaemia diagnosis, there are organisations such as Leukaemia UK which knows the sort of help and support they need. My family remains very grateful for that.**

Debbie, 50, who is in remission from leukaemia



32-36 Loman Street  
London SE1 0EH

Phone: 020 7922 7982  
Email: [hello@leukaemiauk.org.uk](mailto:hello@leukaemiauk.org.uk)

[www.leukaemiauk.org.uk](http://www.leukaemiauk.org.uk)

 Leukaemia UK  @LeukUK

Registered charity: 1150414